Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

Podrobná bibliografie
Hlavní autoři:	Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Médium:	Journal article
Vydáno:	2009

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
Autor: Adams, R, a další
Vydáno: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Autor: Madi, A, a další
Vydáno: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Autor: Madi, A, a další
Vydáno: (2012)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
Autor: Madi, A, a další
Vydáno: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Autor: Adams, R, a další
Vydáno: (2011)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Autor: Adams, R, a další
Vydáno: (2009)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Autor: Maughan, T, a další
Vydáno: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
Autor: Maughan, T, a další
Vydáno: (2010)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Autor: Maughan, T, a další
Vydáno: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
Autor: Adams, R, a další
Vydáno: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Autor: Wasan, H, a další
Vydáno: (2011)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
Autor: Maughan, T, a další
Vydáno: (2010)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Autor: Adams, R, a další
Vydáno: (2008)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Autor: Seymour, M, a další
Vydáno: (2007)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Autor: Wood, G, a další
Vydáno: (2017)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Autor: Seymour, M, a další
Vydáno: (2007)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Autor: Maughan, T, a další
Vydáno: (2010)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Autor: Seymour, M, a další
Vydáno: (2011)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Autor: Maughan, T, a další
Vydáno: (2003)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
Autor: Taieb, J, a další
Vydáno: (2012)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Autor: Madi, A, a další
Vydáno: (2018)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
Autor: Vale, C, a další
Vydáno: (2009)

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Autor: Diana Groza, a další
Vydáno: (2018-05-01)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Autor: Smith, C, a další
Vydáno: (2013)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Autor: Iveson, T, a další
Vydáno: (2018)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
Autor: West, H, a další
Vydáno: (2018)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
Autor: Ji Hoon Choi, a další
Vydáno: (2014-01-01)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
Autor: Mitra, S, a další
Vydáno: (2001)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
Autor: Mukherjee, S, a další
Vydáno: (2017)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Autor: Vale, C, a další
Vydáno: (2012)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
Autor: Vale, C, a další
Vydáno: (2012)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
Autor: J. M. Short, a další
Vydáno: (2023-09-01)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
Autor: Harrison, G, a další
Vydáno: (2000)

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
Autor: Maughan, T, a další
Vydáno: (2002)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
Autor: A. V. Pavlysh, a další
Vydáno: (2015-03-01)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Autor: Vale, C, a další
Vydáno: (2009)

Superiority and non-inferiority: Two sides of the same coin?
Autor: Dunn, D, a další
Vydáno: (2018)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
Autor: Gray, V, a další
Vydáno: (2019)

Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
Autor: Harry Tagbor, a další
Vydáno: (2010-12-01)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
Autor: Violaine Randrian, a další
Vydáno: (2022-06-01)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

Podobné jednotky

Podobné jednotky